Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • seqadmin
    Senior Member
    • Oct 2022
    • 729

    #1

    Largest Catalog of Human Protein-Coding Variation Unveiled

    RGC-ME Dataset Offers Valuable Resource for Precision Medicine Efforts

    In a groundbreaking development, researchers have unveiled the largest catalog of human protein-coding variation to date, providing a rich resource for studying rare coding variants and their implications for disease biology. Derived from exome sequencing of an astonishing 985,830 individuals representing diverse ancestral backgrounds, the catalog offers a comprehensive view of approximately 10.5 million missense and 1.1 million predicted loss-of-function variants (pLOF). With a significant proportion of individuals from populations of African, Admixed American, East Asian, Middle Eastern, and South Asian ancestry, the catalog promises a globally representative dataset. The resource, known as the RGC-ME dataset, aims to accelerate precision medicine efforts and advance our understanding of rare coding variation.

    Rare coding variants that significantly impact gene function can provide crucial insights into the biology of specific genes. However, due to their rarity, identifying and ascertaining the frequency of these variants has traditionally required extensive sample sizes. The vast scope of the RGC-ME dataset, representing nearly one million exomes, enables researchers to delve into the characteristics and frequencies of these rare variants with unprecedented precision.

    Of particular significance is the inclusion of individuals with rare homozygous pLOF variants in over 4,800 genes. Remarkably, this work marks the first documentation of at least one pLOF homozygote for 1,838 of these genes, adding valuable insights to the human knockout catalog. Studying naturally occurring “knockouts” offers a unique opportunity to identify potential drug targets with improved safety profiles, as deeper phenotyping of these individuals can shed light on the implications of gene mutations.

    Moreover, the dataset helps shed light on gene tolerance to loss-of-function mutations and provides refined estimates of selection against heterozygous loss-of-function. By incorporating data from a larger sample size, researchers have identified 3,459 genes intolerant to loss of function, 83 of which were previously assessed as tolerant. Furthermore, 1,241 genes lacking disease annotations have been identified, opening new avenues for exploration and potential disease associations.

    The RGC-ME dataset not only offers insights into loss-of-function variants but also enriches our understanding of missense variation. Researchers have identified 457 genes tolerant to loss-of-function but depleted in missense variation. These findings provide crucial clues about functional regions within genes and aid in distinguishing between pathogenic and benign missense variants.

    In addition to enhancing our understanding of known variants, the dataset also tackles the challenge of variants with unknown or conflicting significance. By employing splicing score thresholds based on empirical variant deleteriousness scores derived from RGC-ME, researchers have been able to identify and interpret cryptic splice sites in approximately 10,708 variants reported in ClinVar.

    An interesting observation from the dataset is the presence of clinically actionable genetic variants in approximately 3% of sequenced individuals, as per the ACMG SF 3.1 list of genes. This finding underscores the potential clinical relevance of incorporating genetic information into medical decision-making processes.

    The researchers behind the RGC-ME dataset have made this invaluable resource accessible to the public through a variant allele frequency browser. By doing so, they aim to foster collaboration and provide researchers with the tools necessary to advance their studies in rare coding variation. This extensive catalog will serve as a vital reference for precision medicine initiatives and aid in unraveling the complex interplay between genetics and disease. Read the official preprint here.
    ​

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
20 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-15-2026, 10:52 AM
0 responses
36 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-14-2026, 05:39 AM
0 responses
42 views
0 reactions
Last Post SEQadmin2  
Working...